Duration of protection after infant hepatitis B vaccination series

Pediatrics

Volumn 133, Issue 6, 2014, Pages

  Middleman, Amy B ^a   Baker, Carol J ^b   Kozinetz, Claudia A ^b   Kamili, Saleem ^c   Nguyen, Chi ^b   Hu, Dale J ^c   Spradling, Philip R ^c  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Adolescent immunization; Hepatitis B; Hepatitis B vaccine; Infant immunization

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; RECOMBINANT HEPATITIS B VACCINE;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ADOLESCENT BEHAVIOR; ADULT; AGE DISTRIBUTION; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG RECHALLENGE; DRUG RESPONSE; DURATION OF PROTECTION; ENDEMIC DISEASE; ETHNICITY; FEMALE; HUMAN; IMMUNIZATION; MALE; PEDIATRICS; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROLOGY; TIME TO TREATMENT; TREATMENT DURATION; UNITED STATES; VACCINATION;

ADOLESCENT IMMUNIZATION; HEPATITIS B; HEPATITIS B VACCINE; INFANT IMMUNIZATION;

ADOLESCENT; AGE FACTORS; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDEMIC DISEASES; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; INFANT; INFANT, NEWBORN; MALE; TEXAS;

EID: 84901825858     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2013-2940     Document Type: Article

References (27)

1. Centers for Disease Control and Prevention. Surveillance for viral hepatitis - United States, 2011. Updated August 19, 2013. Available at: www.cdc.gov/hepatitis/Statistics/2011Surveillance/index.htm. Accessed March 12, 2014
2. Duval B, Gîlca V, Boulianne N, et al. Comparative long term immunogenicity of two recombinant hepatitis B vaccines and the effect of a booster dose given after five years in a low endemicity country. Pediatr Infect Dis J. 2005;24(3):213-218 (Pubitemid 40365854)
3. Gabbuti A, Romanò L, Blanc P, et al. Long-term immunogenicity of hepatitis B vaccination in a cohort of Italian healthy adolescents. Vaccine . 2007;25(16):3129-3132 (Pubitemid 46482746)
4. Tohme RA, Awosika-Olumo D, Nielsen C, et al. Evaluation of hepatitis B vaccine immunogenicity among older adults during an outbreak response in assisted living facilities. Vaccine . 2011;29(50):9316-9320
5. Banatvala J, Van Damme P, Oehen S. Life-long protection against hepatitis B: the role of vaccine immunogenicity in immune memory. Vaccine. 2000;19(7-8):877-885
6. McMahon BJ, Dentinger CM, Bruden D, et al. Antibody levels and protection after hepatitis B vaccine: results of a 22-year follow-up study and response to a booster dose. J Infect Dis. 2009;200(9):1390-1396
7. Kao JT, Wang JH, Hung CH, et al. Long-term efficacy of plasma-derived and recombinant hepatitis B vaccines in a rural township of Central Taiwan. Vaccine. 2009;27(12):1858-1862
8. Samandari T, Fiore AE, Negus S, et al. Differences in response to a hepatitis B vaccine booster dose among Alaskan children and adolescents vaccinated during infancy. Pediatrics. 2007;120(2). Available at: www.pediatrics.org/cgi/content/full/120/2/e373
9. Petersen KM, Bulkow LR, McMahon BJ, et al. Duration of hepatitis B immunity in low risk children receiving hepatitis B vaccinations from birth. Pediatr Infect Dis J. 2004;23(7):650-655 (Pubitemid 38924890)
10. Zanetti AR, Mariano A, Romanò L, et al Study Group. Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet. 2005;366(9494):1379-1384 (Pubitemid 41443405)
11. Bialek SR, Bower WA, Novak R, et al. Persistence of protection against hepatitis B virus infection among adolescents vaccinated with recombinant hepatitis B vaccine beginning at birth: a 15-year follow-up study. Pediatr Infect Dis J. 2008;27(10):881-885
12. Chaves SS, Fischer G, Groeger J, et al. Persistence of long-term immunity to hepatitis B among adolescents immunized at birth. Vaccine. 2012;30(9):1644-1649
13. Yazdanpanah B, Safari M, Yazdanpanah S. Persistence of HBV vaccine's protection and response to hepatitis B booster immunization in 5- to 7 year-old children in the Kohgiloyeh and Boyerahmad Province, Iran. Hepat Mon. 2010;10(1):17-21
14. Poovorawan Y, Chongsrisawat V, Theamboonlers A, Bock HL, Leyssen M, Jacquet JM. Persistence of antibodies and immune memory to hepatitis B vaccine 20 years after infant vaccination in Thailand. Vaccine. 2010;28(3):730-736
15. Centers for Disease Control and Prevention. General recommendations on immunizations: recommendation of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2011;60(2)
16. Middleman AB, Anding R, Tung C. Effect of needle length when immunizing obese adolescents with hepatitis B vaccine. Pediatrics. 2010;125(3). Available at: www.pediatrics.org/cgi/content/full/125/3/e508
17. Brener ND, Kann L, McManus T, Kinchen SA, Sundberg EC, Ross JG. Reliability of the 1999 youth risk behavior survey questionnaire. J Adolesc Health. 2002;31(4):336-342 (Pubitemid 35304631)
18. City of Houston Planning and Development Department. Race/ethnicity city of Houston. Published 2010. Updated May 20, 2013. Available at: www.houstontx.gov/planning/Demographics/docs-pdfs/Cy/Race-Ethnicty-and-Language- Spoken.pdf. Accessed March 12, 2014
19. West DJ. Clinical experience with hepatitis B vaccines. Am J Infect Control. 1989;17(3):172-180 (Pubitemid 19172947)
20. Belser JA, Szretter KJ, Katz JM, Tumpey TM. Use of animal models to understand the pandemic potential of highly pathogenic avian influenza viruses. In: Karl M, Aaron JS, Frederick AM, eds. Advances in Virus Research. Waltham, MA: Academic Press; 2009:55-97
21. Lipatov AS, Kwon YK, Pantin-Jackwood MJ, Swayne DE. Pathogenesis of H5N1 influenza virus infections in mice and ferret models differs according to respiratory tract or digestive system exposure. J Infect Dis. 2009;199(5):717-725
22. Pan LP, Zhang W, Zhang L, et al. CD3Z genetic polymorphism in immune response to hepatitis B vaccination in two independent Chinese populations. PLoS ONE. 2012;7(4):e35303
23. Haralambieva I, Ovsyannikova I, Dhiman N, et al. Common SNP 's/haplotypes in IL18R1 and IL18 genes are associated with variations in humoral immunity to smallpox vaccination in Caucasians and African Americans. J Infect Dis . 2011;204(3):433-441
24. Haralambieva IH, Ovsyannikova IG, Umlauf BJ, et al. Genetic polymorphisms in host antiviral genes: associations with humoral and cellular immunity to measles vaccine. Vaccine. 2011;29(48):8988-8997
25. Li Y, Ni R, Song W, et al. Clear and independent associations of several HLADRB1 alleles with differential antibody responses to hepatitis B vaccination in youth. Hum Genet. 2009;126(5):685-696
26. Saffar MJ, Rezai MS. Long-term antibody response and immunologic memory in children immunized with hepatitis B vaccine at birth. Indian Pediatr. 2004;41(12):1232-1237 (Pubitemid 40101163)
27. Winter AP, Follett EA, McIntyre J, Stewart J, Symington IS. Influence of smoking on immunological responses to hepatitis B vaccine. Vaccine. 1994;12(9):771-772 (Pubitemid 24190555)